

World Journal of *Gastroenterology*

World J Gastroenterol 2023 March 7; 29(9): 1395-1538



REVIEW

- 1395 Molecular mechanisms targeting drug-resistance and metastasis in colorectal cancer: Updates and beyond
Al Bitar S, El-Sabban M, Doughan S, Abou-Kheir W
- 1427 Clinical impact of artificial intelligence-based solutions on imaging of the pancreas and liver
Berbis MA, Paulano Godino F, Royuela del Val J, Alcalá Mata L, Luna A

MINIREVIEWS

- 1446 Role of noncoding RNAs in liver fibrosis
Li QY, Gong T, Huang YK, Kang L, Warner CA, Xie H, Chen LM, Duan XQ
- 1460 Approach to thromboelastography-based transfusion in cirrhosis: An alternative perspective on coagulation disorders
Kataria S, Juneja D, Singh O

ORIGINAL ARTICLE

Basic Study

- 1475 Adenosine 2A receptor contributes to the facilitation of post-infectious irritable bowel syndrome by $\gamma\delta$ T cells via the PKA/CREB/NF- κ B signaling pathway
Dong LW, Chen YY, Chen CC, Ma ZC, Fu J, Huang BL, Liu FJ, Liang DC, Sun DM, Lan C

Retrospective Cohort Study

- 1492 Supply and quality of colonoscopy according to the characteristics of gastroenterologists in the French population-based colorectal-cancer screening program
Koivogui A, Vincelet C, Abihsera G, Ait-Hadad H, Delattre H, Le Trung T, Bernoux A, Carroll R, Nicolet J
- 1509 Comprehensively evaluate the short outcome of small bowel obstruction: A novel medical-economic score system
Xu WX, Zhong QH, Cai Y, Zhan CH, Chen S, Wang H, Tu PS, Chen WX, Chen XQ, Zhang JR

SCIENTOMETRICS

- 1523 Global trend and future landscape of intestinal microcirculation research from 2000 to 2021: A scientometric study
Fu SJ, Xu MT, Wang B, Li BW, Ling H, Li Y, Wang Q, Liu XT, Zhang XY, Li AL, Liu MM

LETTER TO THE EDITOR

- 1536 Thiopurines are an independent risk factor for active tuberculosis in inflammatory bowel disease patients
Fortes FML, Rocha R, Santana GO

ABOUT COVER

Editorial Board Member of *World Journal of Gastroenterology*, Dirk Jacob van Leeuwen, MD, PhD, FAASLD, Adjunct Professor, Section of Gastroenterology and Hepatology, Geisel School of Medicine at Dartmouth College, Hanover, NH 03756, United States. dirk.j.vanleeuwen@gmail.com

AIMS AND SCOPE

The primary aim of *World Journal of Gastroenterology* (WJG, *World J Gastroenterol*) is to provide scholars and readers from various fields of gastroenterology and hepatology with a platform to publish high-quality basic and clinical research articles and communicate their research findings online. WJG mainly publishes articles reporting research results and findings obtained in the field of gastroenterology and hepatology and covering a wide range of topics including gastroenterology, hepatology, gastrointestinal endoscopy, gastrointestinal surgery, gastrointestinal oncology, and pediatric gastroenterology.

INDEXING/ABSTRACTING

The WJG is now abstracted and indexed in Science Citation Index Expanded (SCIE, also known as SciSearch®), Current Contents/Clinical Medicine, Journal Citation Reports, Index Medicus, MEDLINE, PubMed, PubMed Central, Scopus, Reference Citation Analysis, China National Knowledge Infrastructure, China Science and Technology Journal Database, and Superstar Journals Database. The 2022 edition of Journal Citation Reports® cites the 2021 impact factor (IF) for WJG as 5.374; IF without journal self cites: 5.187; 5-year IF: 5.715; Journal Citation Indicator: 0.84; Ranking: 31 among 93 journals in gastroenterology and hepatology; and Quartile category: Q2. The WJG's CiteScore for 2021 is 8.1 and Scopus CiteScore rank 2021: Gastroenterology is 18/149.

RESPONSIBLE EDITORS FOR THIS ISSUE

Production Editor: *Ying-Yi Yuan*; Production Department Director: *Xiang Li*; Editorial Office Director: *Jia-Ru Fan*.

NAME OF JOURNAL

World Journal of Gastroenterology

ISSN

ISSN 1007-9327 (print) ISSN 2219-2840 (online)

LAUNCH DATE

October 1, 1995

FREQUENCY

Weekly

EDITORS-IN-CHIEF

Andrzej S Tarnawski

EDITORIAL BOARD MEMBERS

<http://www.wjgnet.com/1007-9327/editorialboard.htm>

PUBLICATION DATE

March 7, 2023

COPYRIGHT

© 2023 Baishideng Publishing Group Inc

INSTRUCTIONS TO AUTHORS

<https://www.wjgnet.com/bpg/gerinfo/204>

GUIDELINES FOR ETHICS DOCUMENTS

<https://www.wjgnet.com/bpg/GerInfo/287>

GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH

<https://www.wjgnet.com/bpg/gerinfo/240>

PUBLICATION ETHICS

<https://www.wjgnet.com/bpg/GerInfo/288>

PUBLICATION MISCONDUCT

<https://www.wjgnet.com/bpg/gerinfo/208>

ARTICLE PROCESSING CHARGE

<https://www.wjgnet.com/bpg/gerinfo/242>

STEPS FOR SUBMITTING MANUSCRIPTS

<https://www.wjgnet.com/bpg/GerInfo/239>

ONLINE SUBMISSION

<https://www.f6publishing.com>



Thiopurines are an independent risk factor for active tuberculosis in inflammatory bowel disease patients

Flora Maria Lorenzo Fortes, Raquel Rocha, Genoile Oliveira Santana

Specialty type: Gastroenterology and hepatology

Provenance and peer review:

Unsolicited article; Externally peer reviewed.

Peer-review model: Single blind

Peer-review report's scientific quality classification

Grade A (Excellent): 0

Grade B (Very good): 0

Grade C (Good): C, C, C

Grade D (Fair): 0

Grade E (Poor): 0

P-Reviewer: Oley MH, Indonesia; Wang LH, China; Zharikov YO, Russia

Received: November 21, 2022

Peer-review started: November 21, 2022

First decision: December 10, 2022

Revised: January 5, 2023

Accepted: February 22, 2023

Article in press: February 22, 2023

Published online: March 7, 2023



Flora Maria Lorenzo Fortes, Genoile Oliveira Santana, Ciências da Vida, Universidade do Estado da Bahia, Salvador 41150000, Brazil, and Programa de Pós-Graduação em Medicina e Saúde, Universidade Federal da Bahia, Salvador 40110060, Brazil

Raquel Rocha, Ciência da Nutrição, Universidade Federal da Bahia, Salvador 40110160, Brazil

Corresponding author: Raquel Rocha, DSc, Adjunct Associate Professor, Ciência da Nutrição, Universidade Federal da Bahia, Av Araújo Pinho, Salvador 40110160, Brazil.
raquelrocha2@yahoo.com.br

Abstract

The use of thiopurines is an independent risk factor for active tuberculosis in patients with inflammatory bowel disease.

Key Words: Tuberculosis; Inflammatory bowel disease; Thiopurines; Therapy; Risk

©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.

Core Tip: Inflammatory bowel disease (IBD) patients recommended for anti-tumor necrosis factor (anti-TNF) therapy need to be tested for latent tuberculosis (TB) prior to treatment. Azathioprine monotherapy is also an independent risk factor for active TB in patients with IBD. However, the recommendations of the Brazilian Public Health Guideline for Tuberculosis Prevention do not include patients who are receiving immunosuppressive therapy in the risk group for screening for latent TB. We evaluated 301 patients with IBD, and the use of azathioprine treatment increased the risk by 6.87-fold compared to patients without this treatment. The use of anti-TNF therapy had a 10.34-fold increased risk of TB, and the combination of both increased the risk by 17.81-fold.

Citation: Fortes FML, Rocha R, Santana GO. Thiopurines are an independent risk factor for active tuberculosis in inflammatory bowel disease patients. *World J Gastroenterol* 2023; 29(9): 1536-1538

URL: <https://www.wjgnet.com/1007-9327/full/v29/i9/1536.htm>

DOI: <https://dx.doi.org/10.3748/wjg.v29.i9.1536>

TO THE EDITOR

It is known that immunosuppression increases the risk of tuberculosis, especially in countries with a high frequency of active tuberculosis. We read with interest the article published by Fortes *et al*[1], who performed a retrospective cohort study among Inflammatory bowel disease (IBD) patients at a reference center in Brazil, which is a country with a moderate incidence of TB. A total of 301 IBD patients were evaluated; 61.8% had ulcerative colitis, and 38.2% had Crohn's disease. Twenty-seven (9.0%) patients received anti-tumor necrosis factor (anti-TNF α) as a monotherapy, 31 (10.3%) patients received anti-TNF α associated with azathioprine, 3 (1.0%) patients received anti-TNF α treatment associated with methotrexate, and 70 (23.3%) patients received only azathioprine. The use of azathioprine treatment increased the risk by 6.87-fold in comparison to patients without this treatment. The use of anti-TNF therapy showed a 10.34-fold increased risk of TB in this sample, and the association of both increased the risk to 17.81.

Advances in the treatment of IBD have been adopted worldwide. Some post marketing adverse events have been reported, including active tuberculosis (TB) during anti-TNF therapy. It has already been established that the incidence of active TB in this scenario is associated with the TB burden in the geographic region of the study. Brazil is one of the 20 countries in which TB presents a high incidence along with countries from Africa and Asia[2].

IBD patients with a recommendation for anti-TNF therapy need to test for latent TB before treatment. The TNF alpha blocking mechanism, which is critical in stabilizing granulomas during TB infection, would explain this increase in risk. An unanswered question is whether azathioprine in monotherapy is an independent risk factor for active TB in IBD patients[1,3]. A case report published by van Wijngaarden *et al*[4] already drew attention to the development of pleural tuberculosis in a patient with Crohn's disease while receiving azathioprine as the sole immunosuppressive treatment.

Considering that transplant recipients need substantial immunosuppression and azathioprine is one of the drugs used, studies among transplant recipients receiving immunosuppressive therapy helped guide physicians in the care of IBD patients. A Spanish group evaluated the risk factors for active TB after lung transplantation and concluded that the use of azathioprine was identified as an independent risk factor[5].

The recommendations of the Brazilian Public Health Guideline for Tuberculosis Prevention, reviewed in 2020, did not include patients receiving immunosuppressive therapy in the risk group for screening of latent TB[6]. However, consensus from endemic countries suggests investigation and treatment of latent TB before starting immunosuppressive therapy[7-9].

These findings suggest that in areas with a high burden of TB, the use of thiopurines is an independent risk factor for active TB in IBD patients. This evidence needs to be considered when using this therapy for these patients, especially those from countries with a high TB burden. We suggest giving attention to and treating patients with latent tuberculosis and guiding prevention with possible contacts with active tuberculosis. New studies reporting the risk of active TB among IBD patients receiving immunosuppressive therapy from countries with different incidence rates of TB are needed.

FOOTNOTES

Author contributions: Fortes FML designed the study and performed the data analysis; Rocha R reviewed the manuscript and provided technical and material support; and Santana GO contributed to the study design, manuscript revision, supervision of the study, had full access to all of the data in the study and was responsible for the integrity of the data.

Conflict-of-interest statement: Genoile O Santana is on the Advisory Board for Janssen; has received speaking fees from Abbvie, Ferring, Janssen, Takeda, Pfizer and UCB Pharma; and has received research grants from Janssen, Lilly, Pfizer, Roche and Takeda. The other authors declare that they have no conflicts of interest.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <https://creativecommons.org/licenses/by-nc/4.0/>

Country/Territory of origin: Brazil

ORCID number: Flora Maria Lorenzo Fortes 0000-0002-9897-5337; Raquel Rocha 0000-0002-2687-2080; Genoile Oliveira Santana 0000-0001-5936-9791.

S-Editor: Liu GL

L-Editor: A

P-Editor: Liu GL

REFERENCES

- 1 **Fortes FML**, Sorte NB, Mariano VD, Andrade LD, Oliveira FA, Santos MC, Dos Santos CIN, Passos CA, Pacheco MP, Surlo VC, de Almeida NP, Fontes JA, Pimentel AM, Rocha R, Santana GO. Active tuberculosis in inflammatory bowel disease patients under treatment from an endemic area in Latin America. *World J Gastroenterol* 2020; **26**: 6993-7004 [PMID: 33311945 DOI: 10.3748/wjg.v26.i44.6993]
- 2 **Kedia S**, Mouli VP, Kamat N, Sankar J, Ananthakrishnan A, Makharia G, Ahuja V. Risk of Tuberculosis in Patients With Inflammatory Bowel Disease on Infliximab or Adalimumab Is Dependent on the Local Disease Burden of Tuberculosis: A Systematic Review and Meta-Analysis. *Am J Gastroenterol* 2020; **115**: 340-349 [PMID: 32032073 DOI: 10.14309/ajg.0000000000000527]
- 3 **Banerjee R**, Ali RAR, Wei SC, Adsul S. Biologics for the Management of Inflammatory Bowel Disease: A Review in Tuberculosis-Endemic Countries. *Gut Liver* 2020; **14**: 685-698 [PMID: 33191310 DOI: 10.5009/gnl19209]
- 4 **van Wijngaarden P**, Meijssen MA. Tuberculous pleurisy: an unusual complication during treatment of Crohn disease with azathioprine. *Scand J Gastroenterol* 2001; **36**: 1004-1007 [PMID: 11521975 DOI: 10.1080/003655201750305567]
- 5 **Guirao-Arrabal E**, Santos F, Redel-Montero J, Vaquero JM, Cantisán S, Vidal E, Torre-Giménez Á, Rivero A, Torre-Cisneros J. Risk of tuberculosis after lung transplantation: the value of pretransplant chest computed tomography and the impact of mTOR inhibitors and azathioprine use. *Transpl Infect Dis* 2016; **18**: 512-519 [PMID: 27224905 DOI: 10.1111/tid.12555]
- 6 **Brazil**. Ministry of Health. Secretary of Health Surveillance. Department of Communicable Disease Surveillance. Epidemiological Bulletin Special Number -Tuberculosis 2020. Available from: <https://www.gov.br/saude/pt-br/centrais-de-conteudo/publicacoes/boletins/epidemiologicos/especiais/2020/boletim-tuberculose-2020-marcas-1.pdf/view>
- 7 **Kucharzik T**, Ellul P, Greuter T, Rahier JF, Verstockt B, Abreu C, Albuquerque A, Allocca M, Esteve M, Farraye FA, Gordon H, Karmiris K, Kopylov U, Kirchesner J, MacMahon E, Magro F, Maaser C, de Ridder L, Taxonera C, Toruner M, Tremblay L, Scharl M, Viget N, Zabana Y, Vavricka S. ECCO Guidelines on the Prevention, Diagnosis, and Management of Infections in Inflammatory Bowel Disease. *J Crohns Colitis* 2021; **15**: 879-913 [PMID: 33730753 DOI: 10.1093/ecco-jcc/jjab052]
- 8 **Park DI**, Hisamatsu T, Chen M, Ng SC, Ooi CJ, Wei SC, Banerjee R, Hilmi IN, Jeon YT, Han DS, Kim HJ, Ran Z, Wu K, Qian J, Hu PJ, Matsuoka K, Andoh A, Suzuki Y, Sugano K, Watanabe M, Hibi T, Puri AS, Yang SK. Asian Organization for Crohn's and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 1: risk assessment. *Intest Res* 2018; **16**: 4-16 [PMID: 29422793 DOI: 10.5217/ir.2018.16.1.4]
- 9 **Ran Z**, Wu K, Matsuoka K, Jeon YT, Wei SC, Ahuja V, Chen M, Hu PJ, Andoh A, Kim HJ, Yang SK, Watanabe M, Ng SC, Hibi T, Hilmi IN, Suzuki Y, Han DS, Leung WK, Sollano J, Ooi CJ, Qian J. Asian Organization for Crohn's and Colitis and Asia Pacific Association of Gastroenterology practice recommendations for medical management and monitoring of inflammatory bowel disease in Asia. *J Gastroenterol Hepatol* 2021; **36**: 637-645 [PMID: 32672839 DOI: 10.1111/jgh.15185]



Published by **Baishideng Publishing Group Inc**
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Telephone: +1-925-3991568

E-mail: bpgoffice@wjgnet.com

Help Desk: <https://www.f6publishing.com/helpdesk>

<https://www.wjgnet.com>

